Chester County News and Community Website
KING OF PRUSSIA, PA — CSL, a global biotherapeutics leader, recently announced the three-year results from its pivotal HOPE-B study. The findings confirm the long-term durability and safety of HEMGENIX …
Long-Term Efficacy of CSL’s Hemophilia B Gene Therapy, HEMGENIX, Confirmed in Three-Year HOPE-B Study Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics provider, has shared promising top-line results from the Phase 3 trial of TO-208 for molluscum contagiosum (“molluscum”) …
Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently made a significant stride in its quest for innovative vision restoration solutions. The company announced that the first patient …
Ocugen’s Pioneering Gene Therapy OCU410 Takes Major Step Forward in Clinical Trials Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has recently unveiled positive topline results from its Phase 2 signal detection study. The study evaluated the safety and efficacy …
Harmony Biosciences Announces Promising Results from Phase 2 Study on Pitolisant for Myotonic Dystrophy Type 1 Read More
NEWTOWN, PA — Onconova Therapeutics, Inc. (NASDAQ: ONTX) has unveiled preclinical data that demonstrates the superior performance of narazaciclib, a multi-kinase inhibitor, over palbociclib and other CDK4/6 inhibitors. The data …
Onconova Therapeutics Unveils Promising Narazaciclib Preclinical Data at SABCS, Outperforming Other CDK4/6 Inhibitors Read More
PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) has received approval from the U.S. Food and Drug Administration (FDA) to proceed with their Phase 1 clinical trial of CNTY-101 for patients …
FDA Clears Century Therapeutics’ Phase 1 Trial of CNTY-101 for Systemic Lupus Erythematosus Read More PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) has announced it will host a conference call and live audio webcast on Monday, December 11, to discuss preliminary clinical data from its …
Century Therapeutics to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 Trial of CNTY-101 Read More
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …
Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More
BRYN MAWR, PA — Opsidio, LLC, a biopharmaceutical company, has announced the first patient dosing in their Phase 2a clinical trial of OpSCF. This pioneering monoclonal antibody developed by Opsidio …
Opsidio Commences Phase 2a Clinical Trial for Innovative Atopic Dermatitis Treatment Read More
CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (Nasdaq: TRVN), known for its innovative work in developing and commercializing novel medicines for central nervous system disorders, recently announced the acceptance of …
Trevena’s Investigator-Led RELIEVE Study Accepted for Presentation at 2024 American Burn Association Meeting Read More